Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Park Place Capital Corp

Park Place Capital Corp boosted its position in Novo Nordisk A/S (NYSE:NVO) by 33.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,335 shares of the company’s stock after purchasing an additional 335 shares during the quarter. Park Place Capital Corp’s holdings in Novo Nordisk A/S were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $42,000. Albion Financial Group UT grew its position in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the period. Finally, Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the third quarter valued at $48,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NVO opened at $80.59 on Thursday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a 50 day moving average of $96.63 and a two-hundred day moving average of $116.04. The company has a market cap of $361.65 billion, a P/E ratio of 26.08, a P/E/G ratio of 0.89 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Analysts Set New Price Targets

A number of brokerages have issued reports on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.